Leading Company Profile
What is the competitive landscape for LEADING
LEADING has nineteen approved drugs.
Drugs and US Patents for Leading
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leading | LEUCOVORIN CALCIUM | leucovorin calcium | TABLET;ORAL | 213929-001 | Oct 22, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | LEUCOVORIN CALCIUM | leucovorin calcium | TABLET;ORAL | 213929-004 | Oct 22, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 040702-002 | Mar 16, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | FROVATRIPTAN SUCCINATE | frovatriptan succinate | TABLET;ORAL | 216998-001 | Apr 16, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | OXAZEPAM | oxazepam | CAPSULE;ORAL | 218261-001 | Mar 3, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

